New SU2C-Lustgarten Foundation team aims to apply CAR T-cell therapy to pancreatic cancerEurekAlert (press release)The approach is called chimeric antigen receptor (CAR) T-cell therapy, which uses specially modified immune cells to find and destroy can… Continue reading
New SU2C-Lustgarten Foundation team aims to apply CAR T-cell therapy to pancreatic cancerEurekAlert (press release)The approach is called chimeric antigen receptor (CAR) T-cell therapy, which uses specially modified immune cells to find and destroy can… Continue reading
|
Regulatory Recon: AstraZeneca Immunotherapy Fails in Lung Cancer Study; FDA Panel Votes Against Intelli’s Long …
Regulatory Focus Regulatory Recon: AstraZeneca Immunotherapy Fails in Lung Cancer Study; FDA Panel Votes Against Intelli’s Long Acting Opioid (27 July 2017). Posted 27 July 2017 By Michael Mezher. placeholder+image. Welcome to Regulatory Reconnaissance, your … |
|
Regulatory Recon: AstraZeneca Immunotherapy Fails in Lung Cancer Study; FDA Panel Votes Against Intelli’s Long …
Regulatory Focus Regulatory Recon: AstraZeneca Immunotherapy Fails in Lung Cancer Study; FDA Panel Votes Against Intelli’s Long Acting Opioid (27 July 2017). Posted 27 July 2017 By Michael Mezher. placeholder+image. Welcome to Regulatory Reconnaissance, your … |
|
New Stand Up To Cancer-Lustgarten Foundation Research Team Aims To Apply CAR T-cell Therapy to Pancreatic …
PR Newswire (press release) The Stand Up To Cancer–Lustgarten Foundation Chimeric Antigen Receptor T Cell (CART) Translational Research Team is headed by three investigators at the University of Pennsylvania’s Perelman School of Medicine who have been pioneers in CAR … |
|
New Stand Up To Cancer-Lustgarten Foundation Research Team Aims To Apply CAR T-cell Therapy to Pancreatic …
PR Newswire (press release) The Stand Up To Cancer–Lustgarten Foundation Chimeric Antigen Receptor T Cell (CART) Translational Research Team is headed by three investigators at the University of Pennsylvania’s Perelman School of Medicine who have been pioneers in CAR … |
|
CRISPR sheds light on rare pediatric bone marrow failure syndrome
Medical Xpress Because the disease is challenging to study in mice—as mice deficient in telomerase don’t fully experience bone marrow failure—the researchers used CRISPR to edit into human embryonic stem cells two mutations associated with the disease. |